Health Care

Alterity Therapeutics CEO’s option holdings reveal a strategic bet on the company’s future growth, offering investors insight into insider confidence ahead of key clinical milestones.

ASHS Chairman Raymond Stachowiak receives 100k RSUs, signaling board confidence, strategic innovation, and potential upside for investors amid turnaround plans.

Insider selling at Myriad Genetics shows routine portfolio balancing, not a red flag, and highlights strong long‑term confidence amid market volatility.

Oruka insider Joana’s buy‑sell pattern shows disciplined long‑term confidence, boosting investor optimism as analysts upgrade the stock and institutional buying rises.

Silverman’s RSU and option buy signals confidence in Q‑C’s future – learn why insiders are backing the small‑cap health‑care equipment firm and what it means for investors.

CEO Fordyce Marshall sells 22k Vera Therapeutics shares amid bullish 100% YTD gains—insider divestment analysis, market impact, and future outlook.

Insightful look at Myriad Genetics insider sales: COO Mark Verratti’s April 2026 trade, its context, and what it signals for investors.

Monte Rosa insiders sell shares amid bullish trend, yet 52‑week high suggests upside; watch CEO’s periodic divestments for clues on future momentum.

CEO Paul Gudonis buys 19,395 Myomo shares, boosting ownership to 48% and signaling confidence in the company’s robotic‑healthcare future.

CEO Paul Gudonis’s new RSU purchase fuels optimism for Myomo’s growth, showing insider confidence in exoskeleton innovation and potential upside for investors.